3BDO

Research use only, not for human use.

3BDO is a new mTOR activator. 3BDO inhibits autophagy.

3BDO is a new mTOR activator. 3BDO inhibits autophagy.(In Vitro):Adiminstration of 3BDO could dose- and time-dependently decrease FLJ11812 level in HUVECs. Overexpression of FLJ11812 reverses the inhibition of autophagy induced by 3BDO.Adiminstration of 3BDO suppresses the increase in MAP1LC3B puncta induced with rapamycin and it also inhibits the effect of rapamycin in HUVECs. Rapamycin fails to decrease the phosphorylation of MTOR and RPS6KB1 in the presence of 3BDO. The phosphorylation of Ser residues is decreased in HUVECs treated with 10 μM rapamycin, and 60 μM 3BDO reverses the phosphorylation. Adiminstration of 3BDO suppresses the increased MAP1LC3B puncta number, MAP1LC3B-II level and decreased SQSTM1 protein level induced by rapamycin.(In Vivo):Administration of 3BDO increased p-p70S6K levels and decreased ATG13 protein levels in mouse plaque endothelium. Administration of 3BDO stabilizes established atherosclerotic lesions in apoE-/- mice. In apoE-/- mice, serum IL-6 and IL-8 levels were significantly reduced after administration of 3BDO compared to controls . Compared to controls, apoE-/- mice were shown to inhibit endothelial autophagy and apoptosis when administered with 3BDO, thus 3BDO prevents endothelial damage in atherosclerosis.

——

——

——

Apoptosis

Apoptosis

——

——

——

890405-51-3

327.336

C18H17NO5

>98% (HPLC)

In Vitro:?DMSO : ≥ 100 mg/mL (305.50 mM)

[O-][N+](=O)c1ccccc1OCC1CC(Cc2ccccc2)C(=O)O1

——

(-20℃)

With Ice Pack

≥ 2 years